Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey

被引:219
作者
Wittchen, HU
Carter, RM
Pfister, H
Montgomery, SA
Kessler, RC
机构
[1] Max Planck Inst Psychiat, Clin Psychol & Epidemiol Unit, D-80804 Munich, Germany
[2] Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, D-8027 Dresden, Germany
[3] Univ London Imperial Coll Sci Technol & Med, London, England
[4] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
关键词
generalized anxiety disorder; depression; epidemiology; disability; impairment;
D O I
10.1097/00004850-200015060-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Using a nationally representative sample, this study examines the disease-specific impairments of DSM-IV generalized anxiety disorder (GAD) by comparing them to the impairments associated with major depressive disorder (MDD). Results are based on 4181 respondents between the ages of 18-65 years who were interviewed with the 12-month version of the Munich-Composite International Diagnostic Interview as part of the German National Health Interview and Examination Survey-Mental Health Supplement (GHS). After controlling for age, gender, and other psychopathology, 'pure' current GAD without MDD (n = 33), pure MDD (n = 344) and comorbid GAD and MDD (n = 40) were each associated with high impairment as defined by poor self-perceived health, at least 3 days limited or impaired in the past month, and low quality of life scores [from the Short Form-36 Health Survey (SF-36)]. Quality of life scores on several of the SF-36 scales n ere significantly lower for respondents with pure GAD as compared to respondents,vith pure MDD. Overall, the results show that DSM-IV GAD is associated with high impairment even after controlling for other psychopathology. The impairment outcomes for GAD were comparable in size to those for MDD. These findings underline the significance of this disorder from a clinical and social perspective and provide support for the independent diagnostic status Of GAD. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:319 / 328
页数:10
相关论文
共 36 条
  • [1] [Anonymous], 1998, SF 36 FRAGEBOGEN GES
  • [2] [Anonymous], MED CARE
  • [3] BELLACH B, 1997, GESUNDHEITSWESESN, V2, pS59
  • [4] VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE
    BRAZIER, JE
    HARPER, R
    JONES, NMB
    OCATHAIN, A
    THOMAS, KJ
    USHERWOOD, T
    WESTLAKE, L
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6846): : 160 - 164
  • [5] BROWN TA, 1994, AM J PSYCHIAT, V151, P1272
  • [6] DINARDO PA, 1993, ARCH GEN PSYCHIAT, V50, P251
  • [7] SOMATIC SYMPTOM INDEX (SSI) - A NEW AND ABRIDGED SOMATIZATION CONSTRUCT - PREVALENCE AND EPIDEMIOLOGICAL CORRELATES IN 2 LARGE COMMUNITY SAMPLES
    ESCOBAR, JI
    RUBIOSTIPEC, M
    CANINO, G
    KARNO, M
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 1989, 177 (03) : 140 - 146
  • [8] Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder - A 6-month randomized controlled trial
    Gelenberg, AJ
    Lydiard, RB
    Rudolph, RL
    Aguiar, L
    Haskins, JT
    Salinas, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (23): : 3082 - 3088
  • [9] KESSLER RC, 1999, AM J PSYCHIAT, V156, P1663
  • [10] KESSLER RC, 2000, IN PRESS ACTA PSYCHI